Short answer
Altimmune, Inc. (ALT) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expands from nine to eleven directors, adding Peter Greenleaf and Alex Howarth effective November 2, 2026.
Altimmune, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expands from nine to eleven directors, adding Peter Greenleaf and Alex Howarth effective November 2, 2026
- Greenleaf brings former CEO and biopharmaceutical commercial leadership experience, strengthening strategic and industry oversight
- Howarth adds former CFO and operating expertise, relevant to capital allocation, financing and corporate execution
- Each receives options for 160,000 shares plus a $40,000 annual cash retainer, creating shareholder dilution and compensation costs
- Gill, Sayare and Schafer will retire after the 2027 annual meeting, with no stated disagreement, creating planned board turnover
Item 7.01 · Regulation FD Disclosure
- Press release announces new Board appointments, signaling a change in governance and potential strategic oversight
- Exhibit 99.1 contains appointment details, including director identities and effective terms
Item EX-99.1 · Exhibit EX-99.1
- Peter Greenleaf and Alex Howarth join the board November 2, 2026, adding late-stage development, commercialization, licensing and M&A expertise
- Three current directors retire at the 2027 annual meeting, marking planned board succession during Altimmune’s transition toward commercialization
- Board changes support pemvidutide’s Phase 3 MASH development and potential expansion across AUD and ALD indications
- Pemvidutide’s PERFORMA Phase 3 MASH trial began July 2026, while RESTORE enrollment completed in August 2026
- Howarth’s Madrigal experience and Greenleaf’s prior $1.2 billion Sucampo transaction strengthen strategic options, including partnering or M&A execution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Altimmune, Inc. 8-K filings
Get the next ALT 8-K as it lands
Follow ALT for push alerts, or ask the research agent what this filing means.